ArticleNature2024
The genomic landscape of 2,023 colorectal cancers.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis identifies driver genes and characterizes the molecular epidemiology of colorectal cancer.Scientific reports · 2026Pooled it
- Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.British journal of cancer · 2026Trial
- RAS pathway mutations orchestrate chromatin reconfiguration and transcriptional rewiring in colorectal cancer.Cell communication and signaling : CCS · 2026Article
- Hyper-mutational processes provide a head-start for weak cancer drivers: Explaining atypical KRAS variants.PLoS computational biology · 2026Article
- Patient‑specific profiling of TCR‑T cell efficacy enabled by a rapid and standardized reporter system.Protein & cell · 2026Article
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Early-Onset Colorectal Cancer: Clinical and Molecular Features with Emerging Insights from Comprehensive Genomic Profiling.Oncology and therapy · 2026Review
- Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.Cancer cell · 2026Article
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- Prevalence and chronology of colibactin-associated mutational processes and their microbiome spectra in Japanese colorectal cancer.Nature genetics · 2026Article
- Article
- Article
- Early-Onset Colorectal Cancer: From Epidemiologic Shift to Life-Course Carcinogenesis and Age-Attuned Care.Current oncology reports · 2026Review
- Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy.Pharmaceutics · 2026Article
- Identification and validation of a previously missed mutational signature in colorectal cancer.Nature communications · 2026Article
- Next-Generation Sequencing in Colorectal Cancer: Real-World Molecular Profiling and Clinical Correlations.International journal of molecular sciences · 2026Article
- Best practice recommendations for bioinformatics approaches applied to high-throughput sequencing for rare disease and cancer diagnosis within the UK National Health Service.Journal of medical genetics · 2026Article
- Whole Tumor Heterogeneity Topography (WTHT)-A New Approach for Assessment of Intratumor Mutational Heterogeneity in Colorectal Adenomas.International journal of molecular sciences · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- High TMEM161A expression drives malignant phenotypes and predicts poor prognosis in colorectal cancer.iScience · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Alex J Cornish *Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0002-3966-3501
Andreas J Gruber *Department of Biology, University of Konstanz, Konstanz, Germany.ORCID 0000-0001-7664-4257
Ben Kinnersley *Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0003-1783-6296
Daniel Chubb *Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
Anna Frangou *Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-6990-2756
Giulio Caravagna *Department of Mathematics and Geosciences, University of Trieste, Trieste, Italy.ORCID 0000-0003-4240-3265
Boris Noyvert *Cancer Research UK Centre and Centre for Computational Biology, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-4455-1205
Eszter Lakatos *Centre for Evolution and Cancer, Institute of Cancer Research, London, UK.ORCID 0000-0002-7221-6850
Henry M Wood *Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.ORCID 0000-0003-3009-5904
Steve Thorn *Department of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-9962-9356
Richard Culliford *Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0003-4534-9241
Claudia Arnedo-PacInstitute for Research in Biomedicine Barcelona, The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-2037-8487
Jacob HousehamCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.ORCID 0000-0003-3199-336X
William CrossCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.ORCID 0000-0002-4794-8777
Amit SudDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0002-6133-0164
Philip LawDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0001-9663-4611
Maire Ni LeathlobhairTrinity College, Dublin, Ireland.
Aliah HawariManchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, UK.ORCID 0000-0001-6154-5686
Connor WoolleyDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-0770-6968
Kitty SherwoodDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0009-0007-4055-607X
Nathalie FeeleyDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0003-0124-6398
Güler GülEdinburgh Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Juan Fernandez-TajesDepartment of Oncology, University of Oxford, Oxford, UK.
Luis ZapataCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA, USA.ORCID 0000-0003-3596-4515
Nirupa MurugaesuGenomics England, William Harvey Research Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-5005-7908
Alona SosinskyGenomics England, William Harvey Research Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-9022-7409
Jonathan MitchellGenomics England, William Harvey Research Institute, Queen Mary University of London, London, UK.
Nuria Lopez-BigasInstitute for Research in Biomedicine Barcelona, The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-4925-8988
Philip QuirkePathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.ORCID 0000-0002-3597-5444
David N ChurchWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-4617-962X
Ian P M TomlinsonDepartment of Oncology, University of Oxford, Oxford, UK. ian.tomlinson@oncology.ox.ac.uk.ORCID 0000-0003-3037-1470
Andrea SottorivaCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.ORCID 0000-0001-6709-9533
Trevor A GrahamCentre for Evolution and Cancer, Institute of Cancer Research, London, UK.ORCID 0000-0001-9582-1597
David C WedgeManchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, UK.ORCID 0000-0002-7572-3196
Richard S HoulstonDivision of Genetics and Epidemiology, Institute of Cancer Research, London, UK.ORCID 0000-0002-5268-0242
Funding
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6MDetecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4MComprehensive identification of germline-somatic interactionsR01CA269919 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Hannah Kathryn Carter · 2022 to 2026
$2.2MCancer Research UK 27140Cancer Research UK 27963NCI NIH HHS R01 CA269919NCI NIH HHS U54 CA217376NIEHS NIH HHS R01 ES032547Wellcome Trust
Abstract
Colorectal carcinoma (CRC) is a common cause of mortality
Indexed as
Colorectal NeoplasmsGenetic Predisposition to DiseaseGenome, HumanGenomicsMutationAdultAgedAged, 80 and overBRCA1 ProteinChromosomal InstabilityDietDNA Copy Number VariationsFemaleHLA AntigensHumansIsocitrate DehydrogenaseBRCA1 ProteinBRCA1 protein, humancolibactinHLA AntigensIDH1 protein, humanIsocitrate DehydrogenasePeptidesPolyketides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.